Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection
Seonheui Lee ; Jeongae Go ; Kyoung Yul Seo ; Sooyoung Kim ; Eui Sang Chung ; Hyung Joon Kim ; Sangmoo Lee ; Sunyoung Jang ; Min Lee ; R. Doyle Stulting ; Soolienah Rhiu
American Journal of Ophthalmology, Vol.156(3) : 616~622, 2013
American Journal of Ophthalmology
PURPOSE: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection.
DESIGN: Cross-sectional cohort study.
METHODS: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures.
RESULTS: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%).
CONCLUSIONS: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.